Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Senator McConnell's Dilemma: To Serve Patients or Investors? When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights … Continue reading Is Patient Health Being Mortgaged via Derivatives as Homes Were During the Financial Crisis?
Disclosure: This post is the first of several regarding the 2016 Presidential candidates. One post will be done on each major candidate and the focus will be their primary financial backers and their respective foundations. Bill Parish maintains no ties to any candidate nor does he have knowledge of any client owning positions in private … Continue reading Blackstone’s Tony James and Renaissance Technologies Jim Simons, Top Financial Engineers, Back Hillary Clinton Campaign